Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.42 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.41 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.40 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.37 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.37 |
| ▸ | GNPAT | O15228 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CTSK | P43235 | 2/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24486692 | 1.00 | PLA2G2C (0.42) | PLA2G2CSLC22A6FOLH1PLA2G10RIMKLA | |
| SCHEMBL12664911 | 0.95 | PLA2G2C (0.49) | PLA2G2CFOLH1PLA2G10LMNATSHR | |
| SCHEMBL17813082 | 0.88 | PLA2G2C (0.46) | PLA2G2CSLC22A6PLA2G10TSHRCTSK | |
| SCHEMBL17793286 | 0.85 | PLA2G2C (0.63) | PLA2G2CSLC22A6PLA2G10TSHR | |
| SCHEMBL9127074 | 0.85 | PLA2G2C (0.63) | PLA2G2CSLC22A6PLA2G10TSHR | |
| SCHEMBL14240724 | 0.85 | PLA2G2C (0.44) | PLA2G2CSLC22A6PLA2G10LMNATSHR | |
| SCHEMBL12295242 | 0.85 | PLA2G2C (0.44) | PLA2G2CSLC22A6PLA2G10LMNATSHR | |
| SCHEMBL29880335 | 0.85 | PLA2G2C (0.63) | PLA2G2CSLC22A6PLA2G10TSHR | |
| SCHEMBL21686230 | 0.85 | PLA2G2C (0.63) | PLA2G2CSLC22A6PLA2G10TSHR | |
| SCHEMBL12295765 | 0.85 | PLA2G2C (0.41) | PLA2G2CPLA2G10GNPATLMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058932-A1 | ACTIVE INGREDIENT-PEPTIDE CONSTRUCT FOR EXTRACELLULAR CONCENTRATION | MAX PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058932-A1 | ACTIVE INGREDIENT-PEPTIDE CONSTRUCT FOR EXTRACELLULAR CONCENTRATION | VIP, FIBP, MMP7 | PLA2G2C 86/4885SLC22A6 1353/4885FOLH1 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.